Milena Fronza Broering, Pedro Leonidas Oseliero Filho, Pâmela Pacassa Borges, Luis Carlos Cides da Silva, Marcos Camargo Knirsch, Luana Filippi Xavier, Pablo Scharf, Silvana Sandri, Marco Antonio Stephano, Fernando Anselmo de Oliveira, Ibrahim M Sayed, Lionel Fernel Gamarra, Soumita Das, Márcia C A Fantini, Sandra H P Farsky
INTRODUCTION: Inflammatory bowel diseases (IBDs) disrupt the intestinal epithelium, leading to severe chronic inflammation. Current therapies cause adverse effects and are expensive, invasive, and ineffective for most patients. Annexin A1 (AnxA1) is a pivotal endogenous anti-inflammatory and tissue repair protein in IBD. Nanostructured compounds loading AnxA1 or its active N-terminal mimetic peptides improve IBD symptomatology. METHODS: To further explore their potential as a therapeutic candidate, the AnxA1 N-terminal mimetic peptide Ac2-26 was incorporated into SBA-15 ordered mesoporous silica and covered with EL30D-55 to deliver it by oral treatment into the inflamed gut...
2024: International Journal of Nanomedicine